Teva Pharmaceuticals to Present Key Findings
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a prominent player in the biopharmaceutical sector, has announced an exciting upcoming event. The company is set to present data from its successfully completed Phase 3 SOLARIS trial at the Psych Congress Annual Meeting, which is scheduled to take place shortly. This annual gathering, a highly regarded forum for mental health professionals, will allow Teva to share valuable insights from its innovative treatments.
Details of the Conference Call
In connection with this significant presentation, Teva will host a dedicated conference call for analysts and investors. This call is designed to delve deeper into the findings of the SOLARIS trial. Mark your calendars for Monday, September 22, 2025, at 11:00 a.m. ET, when the call will commence. Participants are encouraged to register in advance to obtain necessary dial-in details.
Live Webcast and Archived Access
For those unable to join the live conference call, Teva is ensuring that the presentation remains accessible. A live webcast of the event will be available on Teva’s Investor Relations website. Additionally, an archived version of the webcast will be accessible within 24 hours of the live discussion, allowing interested parties to catch up on all significant points presented.
About Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. is recognized as a leading innovative biopharmaceutical company with deep roots in generics. With over 120 years of operation, Teva has consistently focused on addressing patients’ needs through pioneering work in neuroscience, immunology, and the development of complex generic medicines. The company's commitment to innovation continues as it expands its pipeline of biosimilars and develops groundbreaking treatments.
Core Mission of Teva
At the heart of Teva’s operations lies a mission to improve health outcomes globally. This mission is reflected in their ongoing expansion and the introduction of innovative therapies that aim to address diverse medical needs. As the landscape of healthcare evolves, Teva remains steadfast in its goal to deliver quality medicines to patients.
Understanding the SOLARIS Trial
The SOLARIS trial represents a significant advancement in Teva’s research efforts. Designed to assess the efficacy and safety of Olanzapine LAI (TEV-749), this trial has undergone rigorous testing and evaluation. By sharing the data derived from the trial, Teva aims to provide insights that could influence treatment approaches in the field of psychiatry.
Frequently Asked Questions
What is the SOLARIS trial about?
The SOLARIS trial is a Phase 3 clinical study designed to evaluate the efficacy and safety of Olanzapine LAI (TEV-749) in treating patients with specific psychiatric conditions.
When will the conference call take place?
The conference call is scheduled for September 22, 2025, at 11:00 a.m. ET.
How can I access the live webcast?
The live webcast can be accessed through Teva's Investor Relations website.
Is there an archived version of the webcast?
Yes, an archived version will be available within 24 hours after the live discussion.
How has Teva contributed to the healthcare sector?
Teva has played a critical role in the healthcare sector by developing innovative treatments and a diverse portfolio of generics aimed at improving patient outcomes worldwide.
